Combining Ozonated Autohemotherapy with Pharmacological Therapy for Comorbid Insomnia and Myofascial Pain Syndrome: A Prospective Randomized Controlled Study

Table 2

Change of polysomnography data in the two groups.

	Pretreatment	Posttreatment	1-month	6-month	value^a
					Pre vs. post	Pre vs. 1-month	Pre vs. 6-month
Total sleep time (min)
Control group	355.60 ± 58.49	373.09 ± 58.74	360.58 ± 60.17	357.67 ± 63.87	<0.01	0.11	0.53
O3-AHT group	362.55 ± 58.45	415.20 ± 49.12	421.73 ± 51.86	428.62 ± 48.84	<0.01	<0.01	<0.01
value^b	0.55	<0.01	<0.01	<0.01
Sleep onset latency (min)
Control group	55.93 ± 18.15	49.55 ± 10.81	54.59 ± 14.59	53.43 ± 12.11	<0.01	0.24	0.02
O3-AHT group	54.64 ± 18.44	32.23 ± 15.58	31.85 ± 11.52	25.22 ± 9.32	<0.01	<0.01	<0.01
value^b	0.72	<0.01	<0.01	<0.01
Wake after sleep onset (min)
Control group	83.22 ± 34.24	80.15 ± 20.90	75.57 ± 24.23	78.88 ± 17.11	0.14	<0.01	0.04
O3-AHT group	86.90 ± 35.68	40.39 ± 13.04	39.76 ± 10.77	34.61 ± 12.94	<0.01	<0.01	<0.01
value^b	0.60	<0.01	<0.01	<0.01
Sleep efficiency (%)^c
Control group	72.62 ± 8.89	75.26 ± 10.52	76.87 ± 8.13	73.96 ± 9.53	<0.01	<0.01	0.08
O3-AHT group	73.38 ± 12.18	87.59 ± 6.13	89.11 ± 6.12	91.45 ± 5.93	<0.01	<0.01	<0.01
value^b	0.72	<0.01	<0.01	<0.01
Number of awakenings
Control group	2.87 ± 1.85	2.88 ± 1.18	2.67 ± 1.23	2.79 ± 1.01	0.87	0.10	0.56
O3-AHT group	3.07 ± 1.95	1.52 ± 0.70	1.47 ± 0.97	1.40 ± 1.10	<0.01	<0.01	<0.01
value^b	0.60	<0.01	<0.01	<0.01

Values are the mean ± standard deviation. ^arepeated measures analysis of variance. ^bindependent-samplet-test. ^csleep efficiency = (total sleep time/total time in bed) × 100%. O₃-AHT, ozonated autohemotherapy.